horiz (2)horiz (2)horiz (2)horiz (2)
  • Solutions
    • PepsinCheck
    • Reflux Band
    • Dx-pH System
    • Stretta
    • Secca
  • Clinicians
  • Patients
  • Blog
  • Events
  • Clinical Library
  • Login
✕
Stretta Presentations and New Data at DDW 2017 Highlight Positive Outcomes
May 30, 2017
Restech’s NEW pH software!
August 1, 2017

 

1. SYMPTOMS DON’T TELL THE FULL STORY.

Empiric treatment with medication has long been the standard diagnostic tool for extraesophageal reflux. Presently, this approach is being challenged by new studies that suggest potential damage resulting from anti-reflux drugs. It is further complicated by a placebo effect mitigating symptoms while damaging acid persists. Given the multifactorial nature of laryngopharyngeal reflux, symptoms are not a reliable indication of how well reflux is being controlled.

Patient Symptoms (RSI - RFS) 2F OropH Values IMAGE.jpg

The charts above (adapted from Beaver, 2012) illustrate the similarities in presenting symptoms among patients with positive and negative pH studies.

 

2. OBTAIN A FASTER, MORE RELIABLE DIAGNOSIS.

In 24 hours or less, you can have an evidence-based diagnosis without exposing your patient to a 6-8 week empiric trial, only to arrive at a presumptive diagnosis based on symptom changes. 

  • Negative cases avoid PPI exposure and potential rebound acid hypersecretion
  • Positive cases can be more precisely treated from the beginning vs. partial acid control camouflaged by placebo effect and symptom relief, while damaging exposure persists

 

3. RECORD A BASELINE.

Having a baseline of your patient’s “starting point” on file allows you to determine the efficacy of treatment and explore alternative treatments if needed. 

PRE-TREATMENT pH STUDY RESULTS:

Pre-treatment study results.jpg

POST-TREATMENT IMPROVEMENT:

Post-treatment improvement.jpg

POST-TREATMENT RESOLUTION:

Post-treatment resolution.jpg

 

4. DESIGN A TARGETED TREATMENT PLAN.

Test results support developing a targeted treatment plan, customized for each particular patient’s needs.

  • Titrate medications based on timing and severity of reflux episodes
  • Avoid unnecessary medication
  • Encourage lifestyle modifications for mild or marginal cases
  • Triage for more aggressive treatment for the most severe cases

 

5. ACHIEVE BETTER PATIENT COMPLIANCE.

Studies demonstrate evidence-based treatment results in significantly better patient compliance. Patients tend to comply with the prescribed treatment plan when an objective pH study is performed prior to treatment. 

  Method of Diagnosis Compliance with
medical therapy  (p=.019)
Compliance with
lifestyle modifications (p=.0001)
Reduction in RSI (p=.023)
Group 1 (n=73) pH monitoring 68.5% 82.2% 36.6%
Group 2 (n=70) Empiric treatment with PPIs 50% 25.7% 24.4%

 

 

References:

Beaver ME, Karow CM. Clinical Utility of 24 Hour Pharyngeal pH Monitoring for Hoarseness. J Laryngol Voice. 2012;2(2):60-3.
Friedman M, Maley A, Kelley K, et al. Impact of pH Monitoring on Laryngopharyngeal Reflux Treatment: Improved Compliance and Symptom Resolution. Otolaryngol Head Neck Surg.2011 ;144(4):558-62

Share

Related posts

March 3, 2022

Study finds significant correlation between LPR and Allergic Rhinitis


Read more
January 18, 2021

16 Million New Patients Covered for Stretta Therapy


Read more
November 19, 2020

Minimally Invasive Stretta Antireflux Procedure Accessible to Millions more Patients


Read more
Top 5 Reasons to Add Pharyngeal pH Testing to Your Practice
CONTACT

US: +800.352.1512
Int'l: +1 858.673.3700
Fax: 858.673.3783 contact@restech.com

Contact

Distributor Login
Clinician Login
Representative Login

How we Help

Solutions
PepsinCheck
Reflux Band
Restech
Stretta
Secca

About Us

Company
Contact Us
Job Opportunities
International Distributors
Compliance
Privacy Policy
Terms of Use

Follow Us

Respiratory Technology Corporation 11011 Brooklet Dr, Ste 300 Houston TX 77099 | © 2019 Restech. All Rights Reserved.
    FIND A DOCTOR
      Bree Gorman, VP Marketing

      Bree has been an integral part of Restech from the very beginning. She holds a Masters in Public Health from George Washington University, a BFA from The University of Kansas in Visual Communications, and is a National Board Certified Health & Wellness Coach. Her command of marketing, public health/health delivery systems, and human health behavior change gives her a unique perspective in developing effective marketing strategies for the company.  

      Physicians: Fill out the form below to complete your request to be added to the “Find-A-Doctor” map on restech.com

       


      Thomas Ball, PhD, VP Clinical Affairs

      Thomas previously worked as a polysomnographic technologist in the Virginia Mason system, before  moving into sales with Restech in 2007. After spending 9 years working with distributors across Europe, he was moved into an organizational role at the head office in Houston. In this capacity he works closely with sales and marketing to provide clinical support, manages clinical studies, and provides clinical perspectives on business development. In his spare time Thomas plays rugby for Houston Athletic Rugby Club.

      Jeff Klindworth, VP Business Development

      Jeff has over 30 years of experience in the medical device industry and previously worked in sales at companies such as Encision Inc., Interventional Therapies, LLC, Boston Scientific, and United States Surgical Corporation. He has been working as the VP of Sales for Mederi Therapeutics since 2009 and now brings his extensive expertise to Restech.  Jeff was part of the team that bridged the Mederi asset sale to Restech.  His clinical knowledge of the Stretta and Secca technologies is invaluable.  Jeff has three decades of physician relations experience that he brings to Restech as part of the leadership team.

      Ray Bengermino, VP Sales

      Ray joined Restech in May 2018 as the Vice President for Sales. He has been in the medical device, and specifically in the GERD space for more than 18 years. Starting in sales at Sandhill Scientific pH diagnostics, he moved on to Curon Medical when Stretta and Secca were first introduced to the market. He then worked for Given Imaging when Curon closed operations.  When Stretta was relaunced he joined Mederi as VP of Sales.  Ray was instrumental in keeping Stretta alive and the customer based informed when Mederi ceased operation and assets were purchased by Restech.  He is part of the leadership team directing all product sales for Restech. Ray graduated from Old Dominion University in Norfolk with a BS in Marketing and Business Administration.

      Mark Clark, CPA, CFO

      Mark is a seasoned professional and Certified Public Accountant in Texas who brings a unique blend of creative vision and financial expertise to any leadership team. He worked as a Senior Executive for 15 years on a leadership team which grew a private equity backed cash logistics company performing at negative EBITDA on $100 million revenue into an international industry leader with superior profitability on revenue exceeding $1.5 billion. In addition, he spent 10 years as a Senior Manager at Price Waterhouse delivering results-oriented merger & acquisition, audit and strategic consulting services to middle market clientele including over 40 manufacturing, distribution, service, nonprofit and technology clients. Mark currently serves as a Chief Financial Officer and consulting CFO (seven years) providing in-house and outsourced CFO and transactional services to the middle market.

      Larry Suarez

      Larry is the CTO for Restech and holds a B.S. in Computer Science. He is a software architect specializing in remote patient monitoring, medical sensors, and clinical trial software. Larry holds a patent on massively distributed computing and has worked for a number of major software startup companies including Sybase, Oracle, and Teradata.  Larry was also the co-founder of a startup to deliver advanced clinical pathways to patients using mobile devices and medical sensors. Larry is truly a pioneer and now a veteran in the deployment.

      Jeff Schipper

      Jeff has a breadth of experience with over 25 years in engineering and executive positions within major fortune 100 healthcare companies. He also has proven success in startup medical technology companies. Jeff provides leadership in securing and managing Restech’s patent portfolio. He also built Restech’s compliance platform that established regulatory acceptance in 25+ countries worldwide. Jeff’s scientific support and in-depth understanding of the device industry set the foundation for current and future commercial innovations at Restech.

      Leo Roucher

      With nearly 30 years of working with physician thought leaders developing novel and emerging technologies, Leo has played a key role in the development and evolution of balloon angioplasty and stent technologies that revolutionized the therapy of cardiac disease. His experience was instrumental in the development of the patented platform technology which drives the Restech sensor. Leo provides a vision and passion for effecting change in the diagnosis and management of atypical reflux.

      Deb Krahel

      With over 20 years of executive experience in both the private and public sector, Debra brings a broad understanding of healthcare delivery system. With experience managing products aimed at wide scale disease and population management for 20 million subscribers, Debra has extensive experience in effectively and efficiently developing models of delivery that address specific health issues. Debra has also been involved in the legislative process and served as the elected President of the Independent Physician Association of California. Debra is dedicated to bringing tools to the healthcare market that improve and support the clinical process.